Clinical trial · Interventional
Bubble: A New VR-AI Way of Treatment for Hot Flashes in Women With Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the potential of a unique artificial intelligence-virtual reality intervention called Bubble, to reduce the number and intensity of hot flashes and their accompanying psychological symptoms in women, aged 28-55, with breast cancer. A sample of 37 women with breast cancer were selected to the study. Participants were asked to answer a survey before and after using Bubble. The treatment period was 24 days. The findings are positive and show that the use of Bubble help to reduce several psychological symptoms connected to hot flashes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Hot Flashes | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bubble: A New VR-AI Way of Treatment for Hot Flashes | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- research group
- interventionNames
- Device: Bubble: A New VR-AI Way of Treatment for Hot Flashes
Primary outcomes (15)
- measure
- Demographic and background (disease & treatment-elated) information
- timeFrame
- Through study completion, an average of 1 month
- description
- A form was used to assess demographic information, including birth date, race, education, marital status, employment status, and household income. Women also were asked to record their height and weight, which was used to calculate body mass index. Routine information regarding date of diagnosis, stage of disease, and types and dates of cancer treatments was obtained from medical records
- measure
- HFRDIS, The Hot Flash Related Daily Interference Scale
- timeFrame
- Through study completion, an average of 1 month, before the manipulation
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 28 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Females between the ages of 18 and 60 * Having an existing diagnosis of breast or ovarian cancer * Receiving standard-of-care chemotherapy, endocrine therapy or estrogen blocking anti-cancer treatment * The woman reported experiencing hot flashes at least once per day for a duration of at least 7 days prior to the beginning of the study and hot flashes for at least 30 days prior to the beginning of the study * No chronic migraine headaches, seizure disorders, serious vestibular disorders, or pathological vertigo * No serious psychiatric disorders * Not pregnant * No current substance abuse * Not participating in other forms of therapy * Not using medical marijuana. Exclusion Criteria: \* women aged 28-55 with breast cancer suffering from hot flashes
References
Publications (0)
Data not yet available